InvestorsHub Logo
Followers 86
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: None

Saturday, 08/27/2016 4:13:55 PM

Saturday, August 27, 2016 4:13:55 PM

Post# of 345762
Who has the ear of Robert Garnick?

Barry Karger the Director of the Barnett Institute over at Northeastern knows much about Robert Garnick and how much does Novartis know about PS Targeting? Maybe Tomas Rejtar of Barnett Institute and working at Novartis knows just how important PS Targeting will be...

http://www.northeastern.edu/cos/faculty/barry-karger/

http://www.pressurebiosciences.com/downloads/publications/2011-09/49th%20EHPRG.pdf

Tomas Rejtar:

Investigator III
Novartis
December 2010 – Present (5 years 9 months)

Research Assistant Professor
Northeastern University
1999 – 2010 (11 years)

https://www.linkedin.com/in/tomas-rejtar-89994520

---------------------------------------------------

Now, Garnick came along Oct 19, 2009 and likely as a result of Mr. Jennings so he was brought in for a little bit and ex-Johnson/Johnson. I think this has been brewing for quite some time and Peregrine is certainly hush hush about everything at this time...

http://ir.peregrineinc.com/releasedetail.cfm?ReleaseID=416422


Dave Jennings:

Principal
Jennings Consulting
2009 – 2011 (2 years)

Human Resources consulting, to include talent management, talent acquisition, succession planning, HR strategic planning and mergers and acquisitions. Lead assignment at Peregrine Pharmaceuticals as Interim Vice President, HR.

https://www.linkedin.com/in/dave-jennings-2425ba5

Another

"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News